Advanced/Metastatic Solid Tumors

SOTIO is conducting a multicenter open-label Phase 1/1b study (NCT04234113) to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected relapsed/refractory advanced/metastatic solid tumors. The trial will enroll up to 136 subjects at leading global institutions in the U.S. and EU, including Institut Gustave Roussy (France), Vall d’Hebron Institute of Oncology (Spain) Yale Cancer Center (U.S.) and MD Anderson Cancer Center (U.S.).